%0 Journal Article %1 Onken:2017:Anticancer-Res:28314286 %A Onken, J %A Friesen, C %A Vajkoczy, P %A Misch, M %D 2017 %J Anticancer Res %K cancer dolophine fulltext glioma methadone therapy %N 3 %P 1227-1235 %R 10.21873/anticanres.11438 %T Safety and Tolerance of D,L-Methadone in Combination with Chemotherapy in Patients with Glioma %U https://www.ncbi.nlm.nih.gov/pubmed/28314286 %V 37 %X D,L-Methadone increases sensitivity toward chemotherapy of different tumor cell populations. We evaluated the safety and tolerance of additional use of D,L-methadone in patients with glioma in combination with chemotherapy.The dosage, duration of therapy and side-effects related to D,L-methadone were recorded in 27 patients. Toxicity was assessed accordingly to the Common Toxicity Criteria (CTC) of the National Cancer Institute. Progression-free survival at 6 months (PFS-6) was assessed.A total of 13 patients reported grade 1-3 nausea at the beginning of the D,L-methadone therapy. Four patients reported persistent side-effects of nausea (CTC Grade 2, n=1) and obstipation (CTC grade 2-3, n=3). PFS-6 of patients with glioblastoma was 80% in those with non-methylated O(6)-methylguanine-DNA methyltransferase (MGMT) (n=5) and 100% in those with MGMT methylation (n=7).D,L-methadone can be safely combined with standard glioma chemotherapy without increasing the risk of toxicity or vegetative symptoms such as tachycardia, sweating and restlessness. PFS-6 in patients with primary glioblastoma treated this way seems to be at least comparable to that of historic controls.

@article{Onken:2017:Anticancer-Res:28314286, abstract = {D,L-Methadone increases sensitivity toward chemotherapy of different tumor cell populations. We evaluated the safety and tolerance of additional use of D,L-methadone in patients with glioma in combination with chemotherapy.The dosage, duration of therapy and side-effects related to D,L-methadone were recorded in 27 patients. Toxicity was assessed accordingly to the Common Toxicity Criteria (CTC) of the National Cancer Institute. Progression-free survival at 6 months (PFS-6) was assessed.A total of 13 patients reported grade 1-3 nausea at the beginning of the D,L-methadone therapy. Four patients reported persistent side-effects of nausea (CTC Grade 2, n=1) and obstipation (CTC grade 2-3, n=3). PFS-6 of patients with glioblastoma was 80% in those with non-methylated O(6)-methylguanine-DNA methyltransferase (MGMT) (n=5) and 100% in those with MGMT methylation (n=7).D,L-methadone can be safely combined with standard glioma chemotherapy without increasing the risk of toxicity or vegetative symptoms such as tachycardia, sweating and restlessness. PFS-6 in patients with primary glioblastoma treated this way seems to be at least comparable to that of historic controls.}, added-at = {2017-06-21T19:29:47.000+0200}, author = {Onken, J and Friesen, C and Vajkoczy, P and Misch, M}, biburl = {https://www.bibsonomy.org/bibtex/276993acca392837b7d5fe40d5cd9ffd2/marcsaric}, description = {Safety and Tolerance of D,L-Methadone in Combination with Chemotherapy in Patients with Glioma. - PubMed - NCBI}, doi = {10.21873/anticanres.11438}, interhash = {606095540e29363df1fd4a2207f2fda2}, intrahash = {76993acca392837b7d5fe40d5cd9ffd2}, journal = {Anticancer Res}, keywords = {cancer dolophine fulltext glioma methadone therapy}, month = {03}, number = 3, pages = {1227-1235}, pmid = {28314286}, timestamp = {2017-06-21T19:29:47.000+0200}, title = {Safety and Tolerance of D,L-Methadone in Combination with Chemotherapy in Patients with Glioma}, url = {https://www.ncbi.nlm.nih.gov/pubmed/28314286}, volume = 37, year = 2017 }